Cite

HARVARD Citation

    Früh, M. et al. (2020). Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts. Lung cancer. pp. 6-11. [Online]. 
  
Back to record